Abstracts

NUCLEAR-MITOCHONDRIAL INTERACTIONS AND NEUROCOGNITIVE IMPAIRMENT IN HIV+ ADULTS

HIV-Associated Neurocognitive Disorder (HAND) is a term that captures a wide spectrum of neurocognitive deficits, ranging from mild to severe, in HIV-infected persons. The genetic underpinnings of this complex phenotype are incompletely understood. Abnormalities of mitochondrial function and iron metabolism have long been implicated in neurodegeneration. In this analysis, we aimed to characterize the mitochondrial…

GENETICALLY PREDICTED GENE EXPRESSION AND HIV-ASSOCIATED NEUROCOGNITIVE DISORDER

HIV-Associated Neurocognitive Disorder (HAND) is a term established to capture a spectrum of neurocognitive (NC) deficits associated with HIV infection. The genetic underpinnings of HAND are poorly understood. CHARTER is a U.S.-based observational study of neuro-HIV outcomes in ambulatory, HIV+ adults who underwent standardized, comprehensive NC assessment (2003-7) and were assigned a Global Deficit Score…

CLINICAL PHARMACOLOGY OF THE HIV INTEGRASE STRAND TRANSFER INHIBITOR BICTEGRAVIR

Bictegravir (BIC) is an investigational, once-daily, unboosted HIV integrase strand transfer inhibitor (INSTI) with potent in vitro activity against most INSTI-resistant variants. BIC is currently in development as a single tablet regimen (STR) coformulated with FTC/TAF for treatment of HIV-1 infection in adults and adolescents. Clinical pharmacology assessments of the PK, ADME and DDI potential…

LEDIPASVIR/SOFOSBUVIR RAISES TENOFOVIR DIPHOSPHATE CONCENTRATIONS IN RED CELLS

ACTG 5327 (‘SWIFT-C’) is an ongoing study of sofosbuvir (SOF)-based treatment of acute Hepatitis C virus (HCV) in HIV-infected individuals. We previously reported that participants in Cohort 1 of SWIFT-C taking SOF and ribavirin had 4.3-fold (range 1.4-15.8) higher intracellular tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots (DBS), but there are no data with SOF…

INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPHOID VS GI TISSUES

The majority of persistently HIV-infected cells in patients on suppressive antiretroviral therapy (ART) are in lymphoid tissue. Limited drug uptake by lymphoid tissues may contribute to sustained viral persistence. Identifying tissue sources with differential drug uptake may help guide future HIV eradication strategies. We measured plasma, gut mucosa, and peripheral lymph node drug concentrations from…

PLASMA AND INTRACELLULAR PK OF TENOFOVIR IN PATIENTS SWITCHED FROM TDF TO TAF

Tenofovir alafenamide (TAF), a pro-drug of tenofovir (TFV), has higher intracellular penetration and lower plasma concentrations than tenofovir disoproxil fumarate (TDF). Intraindividual comparisons of plasma and intracellular pharmacokinetics (PK) of TFV and its intracellular metabolite, tenofovir-diphosphate (TFV-DP) have not been described in patients switching from TDF to TAF. We conducted a prospective, non-randomized, cross-over, PK…

RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY

Because of their potency and safety, integrase strand transfer inhibitors (INSTIs) are widely recommended initial HIV-1 treatments in most major treatment guidelines. Bictegravir (BIC, GS-9883) is a novel, unboosted, once-daily INSTI that demonstrated potent activity in a 10-day monotherapy study and has in vitro activity against most INSTI-resistant viruses. Treatment naïve, HIV-infected adults were randomized…